Sarepta Charges Ahead With DMD Gene Therapy Despite Setback

Company Announces Q4 2021 Results

 
• By Alaric DeArment
  
4th quarter computer key on key board
Sarepta talked about plans for its gene therapy for DMD on its 4Q and full-year 2020 earnings call. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from R&D

More from Scrip